Quest Diagnostics Incorporated Q1 2026 Earnings Call Summary

Revenue growth of over 9% was driven almost entirely by organic demand across physician, hospital, and consumer channels, reflecting broad-based adoption of clinical innovations.

The hospital channel achieved double-digit growth primarily through collaborative lab solutions, specifically the Corewell Health implementation which is proceeding smoothly.

Advanced diagnostics in brain health, specifically the AD-Detect Alzheimer’s portfolio, saw revenue more than double year-over-year as physicians increasingly adopt blood-based testing over costly PET/CT scans.

The consumer channel experienced robust growth through questhealth.com and partnerships where Quest serves as the ‘lab engine’ for wearables and health apps.

Operational excellence initiatives, branded as Invigorate, delivered productivity gains through the deployment of automation and AI in both laboratory and administrative functions.

Management attributed a 2.5% increase in revenue per requisition (excluding specific partnerships) to a favorable shift in test mix toward more complex, high-value clinical areas.

Strategic expansion into end-stage renal disease via the Fresenius Medical Care collaboration added significant volume and established a foothold in a new clinical vertical.

Full-year revenue and EPS guidance were raised based on Q1 momentum, though the outlook explicitly excludes any contribution from prospective M&A.

Project Nova, a multi-year initiative to transform order-to-cash processes, is on track for a fall 2027 implementation with $0.25 of dilution expected in 2026.

Guidance assumes a 30 basis point revenue impact from potential ACA disenrollments, though management noted no material impact was observed in the first quarter.

Operating margins are expected to expand for the full year, supported by the ramp-up of the Fresenius partnership toward enterprise average margins by the second half.

Management anticipates continued double-digit growth in advanced diagnostics, supported by new clinical guidelines for biomarkers like Lp(a) and ApoB.

Weather events in January and February resulted in a $9 million revenue headwind, though approximately 70% of canceled appointments were recovered in March.

Higher fuel costs for the company’s transportation fleet and aircraft are expected to create a $7 million to $10 million headwind ($0.05 to $0.07 EPS impact) over the next three quarters.

Management addressed the CMS ‘CRUSH’ initiative, stating Quest had no involvement in the seven proprietary test categories identified and only de minimis exposure to the remaining three genetic or molecular-based tests targeted for oversight.

The PAMA data collection period beginning May 2026 is viewed as a potential catalyst for rate increases if hospital labs comply with reporting requirements as mandated.